Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
David M. Goldenberg(Unknown), Robert M. Sharkey(Immunomedics (United States))
Cited by 464
Related Papers
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
|New England Journal of Medicine|2019|846
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
|Journal of Clinical Oncology|2017|407
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
|Annals of Oncology|2021|371